Nystatin — Resistance of candida albicans isolates from two cases of oral candidiasis

Martin, Michael V.; Dinsdale, R C

doi:10.1016/s0007-117x(82)80026-7

Cited by 14 publications

(7 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We confirmed the validity of our screen by identifying the FDA-approved antifungal drugs in the Enzo library (Table 3), with the exception of nystatin. In agreement with this finding, nystatin-resistant C. albicans isolates were reported (32)(33)(34). At a concentration of 0.3 to 0.7 g/ml, the SADs and the newly identified agents showed comparable degrees of inhibition against C. albicans, such as with fluconazole (MIC, 0.3 g/ml) and haloperidol (MIC, 0.38 g/ml).…”

Section: Discussionsupporting

confidence: 68%

Antifungal Application of Nonantifungal Drugs

Stylianou

Kulesskiy

Lopes

et al. 2014

Antimicrob Agents Chemother

View full text Add to dashboard Cite

cCandida species are the cause of 60% of all mycoses in immunosuppressed individuals, leading to ϳ150,000 deaths annually due to systemic infections, whereas the current antifungal therapies either have toxic side effects or are insufficiently efficient. We performed a screening of two compound libraries, the Enzo and the Institute for Molecular Medicine Finland (FIMM) oncology collection library, for anti-Candida activity based on the European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines. From a total of 844 drugs, 26 agents showed activity against Candida albicans. Of those, 12 were standard antifungal drugs (SADs) and 7 were off-target drugs previously reported to be active against Candida spp. The remaining 7 offtarget drugs, amonafide, tosedostat, megestrol acetate, melengestrol acetate, stanozolol, trifluperidol, and haloperidol, were identified with this screen. The anti-Candida activities of the new agents were investigated by three individual assays using optical density, ATP levels, and microscopy. The antifungal activities of these drugs were comparable to those of the SADs found in the screen. The aminopeptidase inhibitor tosedostat, which is currently in a clinical trial phase for anticancer therapy, displayed a broad antifungal activity against different Candida spp., including Candida glabrata. Thus, this screen reveals agents that were previously unknown to be anti-Candida agents, which allows for the design of novel therapies against invasive candidiasis.

show abstract

Section: Discussionsupporting

confidence: 68%

Antifungal Application of Nonantifungal Drugs

Stylianou

Kulesskiy

Lopes

et al. 2014

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…This finding is significant, as some researchers have speculated that patients with serum precipitins prior to administration of aerosolized steroids may be at a higher risk of developing oral candidosis during such therapy (Spector et al , 1982). In contrast there is a report where two cases of oral candidosis failed to respond to nystatin when used in combination with triamcinolone acetonide (Martin and Dinsdale, 1982). The C. albicans isolates obtained from these patients showed high in vitro resistance to nystatin when tested in combination with triamcinolone acetonide.…”

Section: Clinical Findingsmentioning

confidence: 99%

“…The C. albicans isolates obtained from these patients showed high in vitro resistance to nystatin when tested in combination with triamcinolone acetonide. However, when treated with miconazole nitrate a mycological and clinical cure was obtained in one of the cases (Martin and Dinsdale, 1982). Development of nystatin resistance in Candida is extremely rare, whereas such resistance is relatively common in the azole group of drugs (eg, miconazole).…”

Section: Clinical Findingsmentioning

confidence: 99%

Inhalational and topical steroids, and oral candidosis: a mini review

2001

View full text Add to dashboard Cite

Candidosis is by far the commonest oral fungal infection in man and could manifest as an adverse effect of drug therapy such as inhaled or topically applied corticosteroids. Due to the anti-inflammatory and immunosuppressive effect steroids are used in the management of bronchial asthma and oral mucosal diseases. In this mini review we discuss the clinical and laboratory findings on the relationship between steroid inhalers, other topical steroids and oral candidosis, possible mechanisms of pathogenicity following such therapy as well as the precautions that could be taken to minimize this adverse side effect.

show abstract

“…One of the key challenges associated with the treatment of bacterial and fungal infections with conventional drugs is that a tremendous resistance to antimicrobial drugs can occur, which is thus driving the research for alternative therapies. 11 There are some articles in the literature 12,13 regarding some examples of candidosis that were found to be clinically resistant to nystatin therapy, which makes the treatment of some Candida sp. by nystatin very difficult and requires nystatin to be incorporated into a nano-carrier.…”

Section: Introductionmentioning

confidence: 99%